http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#Head
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#assertion
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#provenance
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#pubinfo
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#assertion
http://purl.obolibrary.org/obo/DOID_526
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_526
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01232
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association
http://www.w3.org/2000/01/rdf-schema#label
invirase in combination with ritonavir and other antiretroviral agents is indicated for the treatment of hiv infection the twice daily administration of invirase in combination with ritonavir is supported by safety data from the maxcmin 1 study see table 6 table 1 in a randomized double blind clinical study nv14256 in zidovudine experienced hiv infected patients invirase in combination with zalcitabine was shown to be superior to either invirase or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to aids defining events or death furthermore in a randomized study actg229 nv14255 patients with advanced hiv infection with history of prolonged zidovudine treatment and who were given invirase 6 mg three times daily zidovudine zalcitabine experienced greater increases in cd4 cell counts as compared to those who received invirase zidovudine or zalcitabine zidovudine it should be noted that hiv treatment regimens that were used in these initial clinical studies of invirase are no longer considered standard of care saquinavir gel capsule 1 mg twice daily coadministered with ritonavir 1 mg twice daily was studied in a heterogeneous population of 148 hiv infected patients maxcmin 1 study at baseline 42 were treatment naive and 1 6 were treatment experienced of which 52 had an hiv rna level 4 copies ml at baseline results showed that 91 148 61 subjects achieved and or sustained an hiv rna level 4 copies ml at the completion of 48 weeks
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01232
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#provenance
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#pubinfo
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#sig
http://purl.org/nanopub/x/hasSignature
N/rMIAQH8jquMe7BsSS7HUOqhWrZACQNBuwj5UgBEXb0lF2Sc+Ps8ud2PeLm3u/7MljUWgY/MoFIefhDnLSSVCWnD4OKg4r7bH3e6K3nghW1on+Tx/Si93TONhSB6khz708vG525cVw04yHPwR4acwVzdSXE4nSqras2HshGnKY=
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
http://purl.org/dc/terms/created
2021-06-14T08:21:22.795+02:00
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAtXJqxJKink3pQq4E0IMbNQKAIn985Sd6TjTXv25-g5M
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs